Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Q Pharma names new vice president of sales and marketing
In this role, Mr Koslow will lead the development and execution of Q Pharma’s sales and marketing efforts, as well as expand the company’s strategic relationships. Q Pharma
In this role, Mr Koslow will lead the development and execution of Q Pharma’s sales and marketing efforts, as well as expand the company’s strategic relationships. Q Pharma
The round was led by DE Shaw Venture Capital of Cupertino, California, and included existing investors the Canadian Medical Discoveries Fund, managed by JovInvestment Management, part of Jovian
The study is the second pivotal Phase III clinical trial for Ophena, a new selective estrogen receptor modulator for the treatment of postmenopausal vaginal syndrome (PVS), a common
In conjunction with Mr Patel’s appointment, Synageva has opened new corporate headquarters outside of Boston in Waltham, Massachusetts. The company maintains research and production operations in the greater
The acquisition of GeneSystems, with its patented approach to rapid microbiological detection equipment and disposables, expands Pall’s total fluid management capabilities in the $1 billion biopharmaceuticals process monitoring
This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In the Phase
The company plans to begin a Phase I clinical trial in early 2010. Azaya is licensing the technology, now known as Azaya Liposomal Encapsulated Radiation Therapy (ALERT), from
The European Commission approval is based on data from three multicenter, randomized, placebo-controlled clinical trials that evaluated the efficacy and safety of Vimpat adjunctive treatment in over 1,300
In this newly created position Mr Cearnal will be directly involved with Cumberland’s commercial strategy and business development initiatives. During his 40-year healthcare career, Mr Cearnal has been
Mr Suen has 18 years of experience in the investment industry both as an investor and as an operator of companies. In 2002, Mr Suen assumed the role